Additional Information

Description

Afluria® 2025-2026 (5 mL Multi-Dose Vial, Flu-106) is an inactivated influenza vaccine indicated for active immunization against influenza virus subtypes A and B. It is formulated for the 2025–2026 flu season, containing antigens corresponding to the strains most likely to circulate. The vaccine is developed using egg-based manufacturing and is approved for individuals aged 6 months and older. 

Each multi-dose vial contains 5 mL of suspension, delivering ten 0.5 mL doses. The vaccine is administered intramuscularly, typically into the deltoid muscle of adults or the anterolateral thigh for younger children. Afluria® does not contain any live virus, and it cannot cause influenza illness. Preservatives, including thimerosal, are present to maintain sterility of the multi-dose format.

Common side effects include injection site pain, redness, swelling, muscle aches, fatigue, and headache. Serious adverse events are rare but may include allergic reactions or Guillain-Barré syndrome. Caution is advised in individuals with a history of severe allergic reaction to previous influenza vaccines, egg proteins, or other vaccine components.